SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported):
November 7, 2012

 
MERIDIAN BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

Ohio
 
0-14902
 
31-0888197
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No. )

 
 
3471 River Hills Drive, Cincinnati, Ohio
 
45244
(Address of principal executive offices)
 
(Zip Code)

 
Registrant’s telephone number, including area code
 
(513) 271-3700

 
 
(Former name or former address, if changed since last report.)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
  o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 

 

Item 2.02.  Results of Operations and Financial Condition.
 
On November 8, 2012, the Company issued a press release announcing its financial results for the fiscal quarter and fiscal year ended September 30, 2012.  A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
 
 
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
 
Meridian’s Board of Directors adopted an amendment to its Amended Code of Regulations effective November 7, 2012.
 
Article III, Section 6(a) (Committees--Appointment) of the Amended Code of Regulations is amended to provide that the minimum number of Directors that may be appointed to constitute a committee is one. Prior to this amendment, the minimum number was three.
 
The Amended Code of Regulations is included as Exhibit 3.2 to this Current Report on Form 8-K, and is incorporated herein by reference.
 
The foregoing summary of the amendment is qualified in its entirety by reference to the specific provisions thereof.
 
 
Item 9.01.  Financial Statements and Exhibits.
 
(d)            Exhibits
 
    3.2  
Amended Code of Regulations, as amended November 7, 2012
   99.1     Press Release dated November 8, 2012
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MERIDIAN BIOSCIENCE, INC.
 
 
 
       
Date:  November 13, 2012
By:
/s/  Melissa A. Lueke  
    Melissa A. Lueke  
   
Executive Vice President and
Chief Financial Officer
 
    (Principal Accounting Officer)  

Exhibit 3.2
 
 

 
AMENDED

CODE OF REGULATIONS

OF

MERIDIAN BIOSCIENCE, INC.


The Code of Regulations of Meridian Bioscience, Inc. is hereby amended in its entirety by the Board of Directors pursuant to Ohio Revised Code Section 1701.11(A)(1)(d) to read as follows as of November 7, 2012.
 
ARTICLE I
FISCAL YEAR
 
Unless otherwise designated by resolution of the Board of Directors, the fiscal year of the Corporation shall commence on the first of day of October of each year.
 

ARTICLE II
SHAREHOLDERS
 
Section 1.    Annual Meetings .
 
The Annual Meeting of the Shareholders of this Corporation, for the election of members of the Board of Directors, the consideration of financial statements and other reports, and the transaction of such other business as may properly be brought before such meeting, shall be held at 3:00 pm Eastern Standard Time, on the third Thursday in January of each year or at such other time and date as determined by the Board of Directors each year.  Upon due notice, there may also be considered and acted upon at an Annual Meeting any matter which could properly be considered and acted upon at a Special Meeting in which case and for which purpose the Annual Meeting shall also be considered as, and shall be a Special Meeting.  In the event the Annual Meeting is not held or if Directors are not elected thereat, a Special Meeting may be called and held for that purpose.
 
Section 2.    Special Meetings .
 
Special meetings of the Shareholders may be held on any business day when called by the Chairman of the Board, the President, a majority of Directors or persons holding twenty-five percent or more of all shares outstanding and entitled to vote.  Only such business shall be brought before the special meeting: (i) pursuant to the Notice of Meeting procedures provided for in Section 4(a) of this Article II; (ii) by or at the direction of the Board of Directors; or (iii) by any Shareholder of the Corporation who was a Shareholder of record both at the time of giving notice by the Shareholder as provided for in Section 5(a) of this Article II for any business other than nominations for election to the Board of Directors and Section 2(a) of Article III of these Regulations for nominations for election to the Board of Directors and at the time of such meeting, who is entitled to vote at the meeting and who has complied with the notice procedures set forth in Section 5(a) of this Article II for any business other than nominations for election to the Board of Directors and Section 2(a) of Article III of these Regulations for nominations for election to the Board of Directors.

 

 

 
Section 3.    Place of Meetings .
 
Any meeting of Shareholders may be held at such place within or without the State of Ohio as may be designated in the Notice of said meeting.
 
Section 4.    Notice of Meeting and Waiver of Notice .
 
                   (a)    Notice .  Written notice of the time, place and purposes of any meeting of Shareholders shall be given to each Shareholder entitled thereto not less than seven days nor more than sixty days before the date fixed for the meeting and as prescribed by law.  Such notice shall be provided by personal delivery, mail, or, to the extent permitted by law, electronically to each Shareholder entitled to notice of or to vote at such meeting.  If such notice is mailed, it shall be directed, postage pre-paid, to the Shareholders at their respective addresses as they appear upon the records of the Corporation, and notice shall be deemed to have been given on the day so mailed.  If any meeting is adjourned to another time or place, no notice as to such adjourned meeting need be given other than by announcement at the meeting at which such an adjournment is taken.  No business shall be transacted at any such adjourned meeting except as might have been lawfully transacted at the meeting at which such adjournment was taken.
 
            (b)    Notice to Joint Owners .  All notices with respect to any shares to which persons are entitled by joint or common ownership may be given to that one of such persons who is named first upon the books of this Corporation, and notice so given shall be sufficient notice to all the holders of such shares.
 
            (c)    Waiver .  Notice of any meeting, whether required to be given by law or under these Regulations, however, may be waived in writing by any Shareholder either before or after any meeting of Shareholders, or by attendance at such meeting without protest to the commencement thereof.
 
Section 5.    Advance Notice of Shareholder Proposals
 
            (a)    Shareholder Proposals Other Than Nominations for Election to the Board of Directors .  The proposal of any business to be considered by the Shareholders other than nominations for election to the Board of Directors may be made at any Annual Meeting of Shareholders or any special meeting as provided for in Section 2 of this Article II: (i) pursuant to the Notice of Meeting procedures provided for in Section 4(a) of this Article II; (ii) by or at the direction of the Board of Directors; or (iii) by any Shareholder of the Corporation who was a Shareholder of record both at the time of giving notice by the Shareholder as provided for in this Section 5(a) and at the time of such meeting, who is entitled to vote at the meeting and who has complied with the notice procedures set forth in this Section 5(a).  For any business other than nominations for election to the Board of Directors to be properly brought before any meeting by a Shareholder pursuant to this Section 5(a), the Shareholder must have given timely notice thereof in writing to the Secretary of the Corporation and such other business must otherwise be a proper matter for action by the Shareholders.  To be timely, a Shareholder’s notice shall set forth all information required by this Section 5 and shall be delivered to the Secretary at the principal executive office of the Corporation not earlier than the one-hundred fiftieth day nor later than 5:00 p.m., Eastern Time, on the ninetieth day prior to such meeting if such meeting is an annual meeting or not later than 5:00 p.m., Eastern Time, on the fifteenth day prior to such meeting if such meeting is a special meeting.  In no event shall the public announcement of a postponement of such meeting or of an adjournment or postponement of any meeting to a later date or time commence a new time period for the giving of a Shareholder’s notice as described above.

- 2 - 
 

 

A Shareholder’s notice to be proper must set forth (i) as to any business that the Shareholder proposes to bring before the meeting, other than nominations to election to the Board of Directors, a description of the business desired to be brought before the meeting, the reasons for proposing such business at the meeting and any material interest in such business of such Shareholder and any Shareholder Associated Person (as defined below), individually or in the aggregate, including any anticipated benefit to the Shareholder or the Shareholder Associated Person therefrom; (ii) as to the Shareholder giving the notice and any Shareholder Associated Person (A) the class, series and number of all shares of stock of the Corporation which are owned by such Shareholder and by such Shareholder Associated Person, if any, (B) the nominee holder for, and the number of, shares owned beneficially but not of record by such Shareholder and by any such Shareholder Associated Person, and (C) whether and the extent to which any hedging or other transaction or series of transactions has been entered into by or on behalf of, or any other agreement, arrangement or understanding (including any short position or any borrowing or lending of shares of stock) has been made, the effect or intent of which is to mitigate loss to or manage risk of stock price changes for, or to increase the voting power of, such Shareholder or any such Shareholder Associated Person with respect to any share of stock of the Corporation; (iii) as to any Shareholder giving notice and any Shareholder Associated Person covered by this Section 5(a), the name and address of such Shareholder, as they appear on the Corporation’s stock ledger and current name and address, if different, and of such Shareholder Associated Person; and (iv) to the extent known by the Shareholder giving the notice, the name and address of any other Shareholder supporting the notice.
 
            (b)    Shareholder Associated Person .  For the purposes of this Section 5 and Section 2 of Article III of these Regulations “Shareholder Associated Person” of any Shareholder shall mean (i) any person controlling, directly or indirectly, or acting in concert with, such Shareholder; (ii) any beneficial owner of shares of stock of the Corporation owned of record or beneficially by such Shareholder; and (iii) any person controlling, controlled by or under common control with such Shareholder Associated Person.
 

            (c)    Inaccurate Information .  If information submitted pursuant to this Section 5 by any Shareholder proposing any business other than a nomination for election to the Board of Directors shall be inaccurate to a material extent, such information may be deemed not to have been provided in accordance with this Section 5.  Upon written request by the Secretary or the Board of Directors, any Shareholder proposing any business other than a nomination for election to the Board of Directors shall provide, within five business days of delivery of such request (or other period as may be specified in such request), (i) written verification, satisfactory, in the discretion of the Board of Directors or any authorized Officer of the Corporation, to demonstrate the accuracy of any information submitted by the Shareholder pursuant to this Section 5; and (ii) a written update of any information previously submitted by the Shareholder pursuant to this Section 5 as of an earlier date.  If the Shareholder fails to provide such written verification or a written update within such period, the information as to which written verification or a written update was requested may be deemed not to have been provided in accordance with this Section 5.  Only such proposals made in accordance with the procedures set forth in this Section 5 shall be eligible to be brought before the meeting.  The Chairman of the meeting shall have the power to determine whether a proposal was made in accordance with this Section 5, and, if any proposal is not in compliance with this Section 5, to declare that such proposal shall be disregarded.
 

- 3 - 
 

 
            (d)     General .  Notwithstanding the foregoing provisions of this Section 5, a Shareholder shall also comply with all applicable requirements of state law and the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder with respect to the matters set forth in this Section 5.  Nothing in this Section 5 shall be deemed to affect the right of a Shareholder to request inclusion of a proposal in, nor the right of the Corporation to omit a proposal from, the Corporation’s proxy statement pursuant to Rule 14a-8 (or any successor provision) under the Securities Exchange Act of 1934.
 
Section 6.    Shareholders Entitled to Notice and to Vote .
 
If a record date shall not be fixed or the books of the Corporation shall not be closed against transfers of shares pursuant to statutory authority, the record date for the determination of Shareholders entitled to notice of or to vote at any meeting of Shareholders shall be the close of business on the twentieth day prior to the date of the meeting and only Shareholders of record at such record date shall be entitled to notice of and to vote at such meeting.  Such record date shall continue to be the record date for all adjournments of such meeting unless a new record date shall be fixed and notice thereof and of the date of the adjourned meeting be given to all Shareholders entitled to notice in accordance with the new record date so fixed.
 
Section 7.    Quorum .
 
At any meeting of Shareholders, the holders of shares entitling them to exercise a majority of the voting power of the Corporation, present in person or by proxy, shall constitute a quorum for such meeting; provided, however, that no action required by law, the Articles, or these Regulations to be authorized or taken by the holders of a designated proportion of the shares of the Corporation may be authorized or taken by a lesser proportion.  The Shareholders present in person or by proxy, whether or not a quorum be present, may adjourn the meeting from time to time without notice other than by announcement at the meeting.
 
Section 8.    Voting Power of Shareholders .
 
Every Shareholder of record of the Corporation shall be entitled at each meeting of Shareholders to one vote for each share of stock held by such Shareholder according to the books and records of the Corporation as of the date of such vote or, if a record date is set by the Board of Directors, as of such record date.
 
 

- 4 - 
 

 
 
Section 9.    Organization of Meetings .
 
            (a)    Presiding Officer .  The Chairman of the Board, or in his absence, the President, or in the absence of both of them, a Vice President of the Corporation, shall call all meetings of the Shareholders to order and shall act as Chairman thereof; if all are absent, the Shareholders shall elect a Chairman.
 
            (b)    Minutes .  The Secretary of the Corporation, or, in his absence, an Assistant Secretary, or, in the absence of both, a person appointed by the Chairman of the meeting, shall act as Secretary of the meeting and shall keep and make a record of the proceedings thereat.
 
Section 10.    Order of  Business .
 
The order of business at all meetings of the Shareholders, unless waived or otherwise determined by a vote of the holder or holders of the majority of the number of shares entitled to vote present in person or represented by proxy, shall be as follows:
 
1.  
Call meeting to order.
 
2.  
Selection of Chairman and/or Secretary, if necessary.
 
3.  
Proof of notice of meeting and presentment of affidavit thereof.
 
4.  
Filing of proxies with Secretary.
 
5.  
Upon appropriate demand, appointment of inspectors of election.
 
6.  
Reading, correction and approval of previously unapproved minutes.
 
7.  
Reports of officers and committees.
 
8.  
If annual meeting, or meeting called for that purpose, election of Directors.
 
9.  
Unfinished business, if adjourned meeting.

10.  
Consideration in sequence of all other matters set forth in the call for and written notice of the meeting.
 
11.  
Any new business other than that set forth in the notice of the meeting which shall have been submitted to the Secretary of the corporation in writing in accordance with the terms and conditions of Section 5 of this Article II.  The provisions of Article III shall govern the procedures for Shareholder nominations of directors.
 
12.  
Adjournment
 
 
 
- 5 -
 

 
 
Section 11.    Voting .
 
Except as provided by statute or in the Articles, every Shareholder entitled to vote shall be entitled to cast one vote on each proposal submitted to the meeting for each share held of record by him on the record date for the determination of the Shareholders entitled to vote at the meeting.  At any meeting at which a quorum is present, all questions and business which may come before the meeting shall be determined by a majority of votes cast, except when a greater proportion is required be law, the Articles, or these Regulations.
 
Section 12.    Proxies .
 
A person who is entitled to attend a Shareholders’ meeting, to vote thereat, or to execute consents, waivers and releases, may be represented at such meeting or vote thereat, and execute consents, waivers, and releases and exercise any of his rights, by proxy or proxies appointed by a writing signed by such person, or by his duly authorized attorney, as provided by the laws of the State of Ohio.
 
Section 13.    List of Shareholders .
 
At any meeting of Shareholders a list of Shareholders, alphabetically arranged, showing the number and classes of shares held by each on the record date applicable to such meeting shall be produced on the request of any Shareholder.
 
ARTICLE III
DIRECTORS
 
Section 1.    General Powers .
 
The authority of this Corporation shall be exercised by or under the direction of the Board of Directors, except where the law, the Articles or these Regulations require action to be authorized or taken by the Shareholders.
 
Section 2.    Election, Number and Qualification of Directors .
 
            (a)    Election .  The Directors shall be elected at the Annual Meeting of the Shareholders, or if not so elected, at a special meeting of Shareholders called for that purpose provided that the Board of Directors has determined that Directors shall be elected at such special meeting.  Nominations for election to the Board of Directors may be made at any such meeting described in the previous sentence (i) pursuant to the Notice of Meeting procedures provided for in Section 4(a) of Article II of these Regulations; (ii) by or at the direction of the Board of Directors; or (iii) by any Shareholder of the Corporation who was a Shareholder of record both at the time of giving notice by the Shareholder as provided for in this Section 2(a) and at the time of the meeting, who is entitled to vote at the meeting and who has complied with the notice procedures set forth in this Section 2(a).  For a nomination for election to the Board of Directors to be properly brought before any meeting by a Shareholder pursuant to this Section 2(a), the Shareholder must have given timely notice thereof in writing to the Secretary of the Corporation.  To be timely, a Shareholder’s notice shall set forth all information required by this Section 2 and shall be delivered to the Secretary at the principal executive office of the Corporation not earlier than the one-hundred fiftieth day nor later than 5:00 p.m., Eastern Time, on the ninetieth day prior to such meeting if such meeting is an annual meeting or not later than 5:00 p.m., Eastern Time, on the fifteenth day prior to such meeting if such meeting is a special meeting.  In no event shall the public announcement of a postponement of such meeting or of an adjournment or postponement of meeting to a later date or time commence a new time period for the giving of a Shareholder’s notice as described above.  Only persons nominated as provided for in this Section 2(a) shall be eligible for election.
 

- 6 - 
 

 
 
A Shareholder’s nomination to be proper must set forth (i) as to each individual whom the Shareholder proposes to nominate for election or reelection as a Director (A) the name, age, business address and residence address of such individual, (B) the class, series, and number of any shares of stock of the Corporation that are beneficially owned or owned of record by such individual, (C) the date such shares were acquired and the investment intent of such acquisition and (D) all other information relating to such individual that is required to be disclosed in solicitations of proxies for election of Directors in an election contest (even if an election contest is not involved), or is otherwise required, in each case pursuant to Regulation 14A (or any successor provision) under the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder (including such individuals written consent to being named in the proxy statement as a nominee and to serving as a Director if elected); (ii) as to the Shareholder giving the notice and any Shareholder Associated Person (A) the class, series and number of all shares of stock of the Corporation which are owned by such Shareholder and by such Shareholder Associated Person, if any, (B) the nominee holder for, and the number of, shares owned beneficially but not of record by such Shareholder and by any such Shareholder Associated Person, and (C) whether and the extent to which any hedging or other transaction or series of transactions has been entered into by or on behalf of, or any other agreement, arrangement or understanding (including any short position or any borrowing or lending of shares of stock) has been made, the effect or intent of which is to mitigate loss to or manage risk of stock price changes for, or to increase the voting power of, such Shareholder or any such Shareholder Associated Person with respect to any share of stock of the Corporation; (iii) as to any Shareholder giving notice and any Shareholder Associated Person covered by this Section 2(a), the name and address of such Shareholder, as they appear on the Corporation’s stock ledger and current name and address, if different, and of such Shareholder Associated Person; and (iv) to the extent known by the Shareholder giving the notice, the name and address of any other Shareholder supporting the nominee for election or reelection as a Director.
 
            (b)    Number .  The number of Directors, which shall not be less than three, may be fixed or changed at a meeting of the Shareholders called for the purpose of electing Directors at which a quorum is present, by the affirmative vote of the holders of a majority of the shares represented at the meeting and entitled to vote on such proposal.  In addition, the number of Directors may be fixed or changed by action of the Directors at a meeting called for that purpose at which a quorum is present by a majority vote of the Directors present at the meeting.  The Directors then in office may fill any Director’s office that is created by an increase in the number of Directors.  The number of Directors elected shall be deemed to be the number of Directors fixed unless otherwise fixed by resolution adopted at the meeting at which such Directors are elected.
 
            (c)    Shareholder Nominations .  If information submitted pursuant to this Section 2 by any Shareholder proposing a nominee for election as a Director shall be inaccurate to a material extent, such information may be deemed not to have been provided in accordance with this Section 2.  Upon written request by the Secretary or the Board of Directors, any Shareholder proposing a nominee for election as a Director shall provide, within five business days of delivery of such request (or other period as may be specified in such request), (i) written verification, satisfactory, in the discretion of the Board of Directors or any authorized Officer of the Corporation, to demonstrate the accuracy of any information submitted by the Shareholder pursuant to this Section 2 and (ii) a written update of any information previously submitted by the Shareholder pursuant to this Section 2 as of an earlier date.  If the Shareholder fails to provide such written verification or a written update within such period, the information as to which written verification or a written update was requested may be deemed not to have been provided in accordance with this Section 2.  Only such individuals who are nominated in accordance with the procedures set forth in this Section 2 shall be eligible for election by Shareholders as Directors.  The Chairman of the meeting shall have the power to determine whether a nomination was made in accordance with this Section 2, and, if any proposed nomination is not in compliance with this Section 2, to declare that such nomination shall be disregarded.
 
            (d)    Qualifications .  Directors need not be Shareholders of the Corporation.
 
Section 3.    Term of Office of Directors .
 
            (a)    Term .  Each Director shall hold office until the next annual meeting of the Shareholders and until his successor has been elected or until his earlier resignation, removal from office, or death.  Directors shall be subject to removal as provided by statute or by other lawful procedures and nothing herein shall be construed to prevent the removal of any or all Directors in accordance therewith.
 
            (b)    Resignation .  A resignation from the Board of Directors shall be deemed to take effect immediately upon its being received by any incumbent corporate officer other than an officer who is also the resigning Director, unless some other time is specified therein.
   
            (c)    Vacancy .  In the event of any vacancy in the Board of Directors for any cause, including, but not limited to, those caused by an increase in the number of Directors, the remaining Directors, though less than a majority of the whole Board, may fill any such vacancy for the unexpired term.
 

- 7 - 
 

 

Section 4.    Meetings of Directors .
 
            (a)    Regular Meetings .  A regular meeting of the Board of Directors shall be held immediately following the adjournment of the annual meeting of the Shareholders or a special meeting of the Shareholders at which Directors are elected.  The holding of such Shareholders’ meeting shall constitute notice of such Directors’ meeting and such meeting shall be held without further notice.  Other regular meetings shall be held at such other times and places as may be fixed by the Directors.
 
            (b)    Special Meetings .  Special Meetings of the Board of Directors may be held at any time upon call of the Chairman of the Board, the President, any Vice President, or any two Diretors.
 
            (c)    Place of Meeting .  Any meeting of Directors may be held at such place within or without the State of Ohio as may be designated in the Notice of said meeting.
 
            (d)    Notice of Meeting and Waiver of Notice .  Notice of the time and place of any regular or special meeting of the Board of Directors (other than the regular meeting of Directors following the adjournment of the annual meeting of the Shareholders or following any special meeting of the Shareholders at which Directors are elected) shall be given to each Director by personal delivery, telephone, mail, or by electronic delivery at least forty-eight hours before the meeting, which notice need not specify the purpose of the meeting.  Such notice, however, may be waived in writing by any Director either before or after any such meeting, or by attendance at such meeting without protest prior to the commencement thereof.
 
            (e)    Meetings by Communications Equipment .  Members of the Board or any committee designated by the Board may participate in a meeting of such Board or committee by means of a conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other at the same time.  Participation by such means shall constitute presence in person at a meeting.
 
Section 5.    Quorum and Voting .
 
At any meeting of Directors, not less than one-half of the whole authorized number of Directors is necessary to constitute a quorum for such meeting, except that a majority of the remaining Directors in office constitutes a quorum for filling a vacancy in the Board.  At any meeting at which a quorum is present, all acts, questions, and business which may come before the meeting shall be determined by a majority of votes cast by the Directors present at such meeting, unless the vote of a greater number is required by the Articles, or these Regulations or By-Laws duly adopted by the Board of Directors.
 

- 8 - 
 

 

 
Section 6.    Committees .
 
            (a)    Appointment .  The Board of Directors may from time to time appoint certain of its members (but in no event less than one) to act as a committee or committees in the intervals between meetings of the Board and may delegate to such committee or committees power to be exercised under the control and direction of the Board.  Each such committee and each member thereof shall serve at the pleasure of the Board.
 
            (b)    Executive Committee .  In particular, the Board of Directors may create from its membership and define the powers and duties of an Executive Committee.  During the intervals between meetings of the Board of Directors, the Executive Committee shall possess and may exercise all of the powers of the Board of Directors in the management and control and the business of the Corporation to the extent permitted by law.  All action taken by the Executive Committee shall be reported to the Board of Directors at its first meeting thereafter.
 
            (c)    Committee Action .  Unless otherwise provided by the Board of Directors, a majority of the members of any committee appointed by the Board of Directors pursuant to this Section shall constitute a quorum at any meeting thereof and the act of a majority of the members present at a meeting at which a quorum is present shall be the act of such committee.  Action may be taken by any such committee without a meeting by a writing signed by all its members.  Any such committee shall prescribe its own rules for calling and holding meetings and its method of procedure, subject to any rules prescribed by the Board of Directors, and shall keep a written record of all action taken by it.
 
Section 7.    Action of Directors Without a Meeting .
 
Any action which may be taken at a meeting of Directors or any Committee thereof may be taken without a meeting, if authorized by a writing or writings signed by all the Directors, which writing or writings shall be filed or entered upon the records of the Corporation.
 
Section 8.    Compensation of Directors .
 
The Board of Directors may allow compensation for attendance at meetings or for any special services, may allow compensation to the member of any committee, and may reimburse any Director for his expenses in connection with attending any Board or committee meeting.

Section 9.    Relationship with Corporation .
 
Directors shall not be barred from providing professional or other services to the Corporation.  No contract or transaction shall be void or voidable with respect to the Corporation for the reason that it is between the Corporation and one or more of its Directors, or between the Corporation and any other person in which one or more of its Directors are directors, trustees or officers or have a financial or personal interest, or for the reason that one or more interested Directors participate in or vote at the meeting of the Directors or committee thereof which authorizes such contract or transaction, if in any such case (a) the material facts as to the Director’s relationship or interest and as to the contract or transaction are disclosed or are known to the Directors or the committee and the Directors or committee, in good faith, reasonably justified by such facts, authorized the contract or transaction by the affirmative vote of a majority of the disinterested Directors, even though the disinterested Directors constitute less than a quorum; or (b) the material facts as to the Director’s relationship or interest and as to the contract or transaction are disclosed or are known to the Shareholders entitled to vote thereon and the contract or transaction is specifically approved at a meeting of the Shareholders held for such purpose by the affirmative vote of the holders of shares entitling them to exercise a majority of the voting power of the Corporation held by persons not interested in the contract or transaction; or (c) the contract or transaction is fair as to the Corporation as of the time it is authorized or approved by the Directors, a committee thereof or the Shareholders.
 

- 9 - 
 

 

 
Section 10.    Attendance at Meetings of Persons Who Are Not Directors .
 
Unless waived by a majority of Directors in attendance, not less than twenty-four hours before any regular or special meeting of the Board of Directors any Director who desires the presence at such meeting of not more than one person who is not a Director shall so notify all other Directors, request the presence of such person at the meeting, and state the reason in, writing.  Such person will not be permitted to attend the Directors’ meeting unless a majority of the Directors in attendance vote to admit such person to the meeting.  Such vote shall constitute the first order of business for any such meeting of the Board of Directors.  Such right to attend, whether granted by waiver or vote, may be revoked at any time during any such meeting by the vote of a majority of the Directors in attendance.
 
ARTICLE IV
OFFICERS
 
Section 1.    General Provisions.
 
The Board of Directors shall elect a President, a Secretary and a Treasurer, and may elect a Chairman of the Board, one or more Vice Presidents, and such other officers and assistant officers as the Board may from time-to-time deem necessary.  The Chairman of the Board, if any, and the President shall be Directors, but no one of the other officers need be a Director.  Any two or more offices may be held by the same person, but no officer shall execute, acknowledge or verify any instrument in more than one capacity of such instrument is required to be exe­cuted, acknowledged or verified by two or more officers.
 
Section 2.    Powers and Duties .
 
All officers, as between themselves and the Corporation, shall respectively have such authority and perform such duties as are customarily incident to their respective offices, and as may be specified from time to time by the Board of Directors, regardless of whether such authority and duties are customarily incident to such office.  In the absence of any officer of the Corporation, or for any other reason the Board of Directors may deem sufficient, powers or duties of such officer, or any of them may be delegated, to any other officer or to any Director.  The Board of Directors may from time to time delegate to any officer authority to appoint and remove subordinate officers and to pre­scribe their authority and duties.  Since the lawful purposes of this Corporation includes the acquisition and ownership of real property, personal property and property in the section of the Corporation’s property rights in its patents, copyrights and trademarks, each of the officers of this Corporation is empowered to execute any power of attorney necessary to protect, secure, or vest the Corporation’s interest in and to real property, personal property and its property protectable by patents, trademarks and copyright registrations and to secure such patents, copyrights and trademark registrations.
 
Section 3.    Term of Office and Removal .
 
            (a)    Term .  Each officer of the Corporation shall hold office at the pleasure of the Board of Directors, and unless sooner removed by the Board of Directors, until the meeting of the Board of Directors following the date of election of Directors and until his successor is elected and qualified.
 
            (b)    Removal .  The Board of Directors may remove any officer at any time with or without cause by the affirmative vote of a majority of Directors then in office.
 
Section 4.    Compensation of Officers .
 
Unless compensation is otherwise determined by a majority of the Directors at a regular or special meeting of the Board of Directors or unless such determination is delegated by the Board of Directors to another officer or officers, the President of the Corporation from time to time shall determine the compensation to be paid to all officers and other employees for services rendered to the Corporation.
 
 
- 10 -
 

 
ARTICLE V
INDEMNIFICATION OF DIRECTORS AND OFFICERS
 
Section 1.    Right of Indemnification .
 
Each Director, officer and member of a committee of this Corporation, and any person who may have served at the request of this Corporation as a Director, trustee, officer, employee or agent of any other corporation, partnership, joint venture, trust or other enterprise, such person’s heirs, executors and administrators, shall be indemnified and held harmless by the Corporation, to the furthest extent permitted by law as then in effect, against all costs and expenses reasonably incurred by such person concerning, or in connection with, the defense of any claim asserted or suit or proceeding brought against such person by reason of that person’s conduct or actions in such capacity at the time of incurring such costs or expenses, except costs and expenses incurred in relation to matters as to which such person shall have been willfully derelict in the performance of that person’s duty.  Such costs and expenses shall include the cost of reasonable settlements (with or without suit), judgments, attorneys’ fees, costs of suit, fines and penalties and other liabilities (other than amounts paid by any such person to this Corporation or any subsidiary thereof).  The right to indemnification conferred in this Section 1 shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any proceeding in advance of its final dispositions (hereinafter an “advancement of expenses”).  Any advancement of expenses shall be made only upon delivery to the Corporation of an undertaking by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses under this Section 1.  To the extent any of the indemnification provisions set forth above prove to be ineffective for any reason in furnishing the indemnification provided, each of the persons named above shall be indemnified by the Corporation to the full extent authorized by the General Corporation Law of Ohio.
 
Section 2.    Definition of Performance .
 
For the purposes of this Article, a Director, officer or member of a committee shall conclusively be deemed not to have been willfully derelict in the performance of such person’s duty as such Director, officer or member of committee:
 
            (a)    Determination by Suit .  In a matter which shall have been the subject of a suit or proceeding in which such person was a party which is disposed of by adjudication on the merits, unless such person shall have been finally adjudged in such suit or proceeding to, have been willfully derelict in the performance of that person’s duty as such Director, officer or member of a committee; or
 
            (b)    Determination by Committee .  In a matter not falling within (a) above, a majority of disinterested members of the Board of Directors or a majority of a committee of disinterested Shareholders of the Corporation, selected as hereinafter provided, shall determine that such person was not willfully derelict.  Such determination shall be made by the disinterested members of the Board of Directors except where such members shall determine that such matter should be referred to said committee of disinterested Shareholders.
 
Section 3.    Selection of Committee .
 
The selection of a committee of Shareholders provided above may be made by the majority vote of the disinterested Directors or, if there be no disinterested Director or Directors, by the chief executive officer of the Corporation.  A Director or Shareholder shall be deemed disinterested in a matter if such person has no interest therein other than as a Director or Shareholder of the Corporation as the case may be.  The Corporation shall pay the fees and expenses of the Shareholders or Directors, as the case may be, incurred in connection with making a determination as above provided.
 
Section 4.    Non-Committee Determination .
 
In the event that a Director, officer or member of a committee shall be found by some other method not to have been willfully derelict in the performance of such person’s duty as such Director, officer or member of a committee, then such determination as to dereliction shall not be questioned on the ground that it was made otherwise than as provided above.
 

 
- 11 - 
 

 

Section 5.     Indemnification by Law or Contract .
 
The foregoing rights of indemnification and payment of expenses shall not be exclusive of, and shall be in addition to any rights to which any such person may otherwise be entitled as a matter of law or by contract with the Corporation which is expressly permitted hereby.
 
Section 6.    Insurance .
 
The Corporation may, to the full extent then permitted by law and authorized by the Board of Directors, purchase and maintain insurance or furnish similar protection, including but not limited to trust funds, letters of credit or self-insurance, on behalf of or for any persons described in this Article V, against any liability asserted against and incurred by any such person in any such capacity, or arising out of his status as such, whether or not the Corporation would have the power to indemnify such person against such liability.  Insurance may be purchased from or maintained with a person in which the Corporation has a financial interest.
 
Section 7.    Miscellaneous .
 
The right of indemnification conferred hereby shall be extended to any threatened action, suit or proceeding, and the failure to institute it shall be deemed its final determination.  Advances may be made by the Corporation against costs, expenses and fees, as and upon the terms, determined by the Board of Directors.
 
ARTICLE VI
SECURITIES HELD BY THE CORPORATION
 
Section 1.    Transfer of Securities Owned by the Corporation .
 
All endorsements, assignments, transfers, stock powers, share powers or other instruments of transfer of securities standing in the name of the Corporation shall be executed for and in the name of the Corporation by the President, by a Vice President, by the Secretary or by the Treasurer or by any other person or persons as may be thereunto authorized by the Board of Di­rectors.
 
Section 2.    Voting Securities Held by the Corporation .
 
The Chairman of the Board, President, and Vice President, Secretary or Treasurer, in person or by another person thereunto authorized by the Board of Directors, in person or by proxy or proxies appointed by him, shall have full power and authority on behalf of the Corporation to vote, act and consent with respect to any securities issued by other corporations which the Corporation may own.
 

- 12 - 
 

 
ARTICLE VII
SHARE CERTIFICATES

 
Section 1.    Transfer and Registration of Certificates .
 
The Board of Directors shall have authority to make such rules and regulations, not inconsistent with law, the Articles or these Regulations, as it deems expedient concerning the issuance, transfer and registration of certificates for shares’ and the shares represented thereby and may appoint transfer agents and registrars thereof.
 
Section 2.    Uncertificated Shares of Stock; Stock Certificates .
 
The Board of Directors may provided by resolution, to the extent permitted by applicable law and unless otherwise provided by the Articles or these Regulations, that some or all of any or all classes and series of shares of stock of the Corporation shall be issued in uncertificated form pursuant to customary arrangements for issuing shares in such uncertificated form, including by electronic or other means.  Any such resolution shall not apply to shares then represented by a certificate until such certificate is surrendered to the Corporation, nor shall such a resolution apply to a certificated share issued in exchange for an uncertificated share.  Within a reasonable time after the issuance or transfer of uncertificated shares, the Corporation shall send to the registered owner of the shares a written notice containing the information required to be set forth or stated on certificates pursuant to applicable law.  Notwithstanding the foregoing, upon the written request of a holder of shares of the Corporation delivered to the Secretary, such holder is entitled to receive one or more certificates representing the shares of stock of the Corporation held by such holder.  Any such certificate shall be signed by the Chairman of the Board, the President or a Vice President and the Secretary or Treasurer or an Assistant Secretary, and sealed with the seal of the Corporation.  Such signatures and/or seal may be a facsimile, engraved or printed.  In case any such officer who has signed any such certificate shall have ceased to be such officer before such certificate is delivered by the Corporation, it may nevertheless be issued and delivered by the Corporation with the same effect as if such officer had not ceased to be such at the date of its delivery.  Any certificate representing the stock of the Corporation shall be in such form as shall be approved by the Board of Directors and shall conform to the requirements of the laws of the State of Ohio.
 
Section 3.    Substituted Certificates .
 
Any person claiming that a certificate for shares has been lost, stolen or destroyed, shall make an affidavit or affirmation of that fact and, if required, shall give the Corporation (and its registrar or registrars and its transfer agent or agents, if any) a bond of indemnity, in such form and with one or more sureties satisfactory to the Board, and, if required by the Board of Directors, shall advertise the same in such manner as the Board of Directors may require, where upon a new certificate may be executed and delivered of the same tenor and for the same number of shares as the one alleged to have been lost, stolen or destroyed.
 
ARTICLE VIII
CONSISTENCY WITH ARTICLES OF INCORPORATION
 
If any provisions of these Regulations shall be inconsistent with the Corporation’s Articles of Incorporation (and as they may be amended from time to time), the Articles of Incorporation (as so amended at the time) shall govern.
 
ARTICLE IX
SECTION HEADINGS
 
The headings contained in this Code of Regulations are for reference purposes only and shall not be construed to be part of and/or shall not affect in any way the meaning or interpretation of this Code of Regulations.
 
ARTICLE X
AMENDMENTS
 
This Code of Regulations of the Corporation (and as it may be amended from time-to-time) may be amended or added to by the affirmative vote or the written consent of the Shareholders of record entitled to exercise a majority of the voting power on such proposal or by the directors to the extent permitted by the Ohio Revised Code; provided, however, that if an amendment or addition is adopted by written consent without a meeting of the Shareholders or otherwise by the directors, it shall be the duty of the Secretary to enter the amendment or addition in the records of the Corporation, and to provide notice to Shareholders to the extent required by applicable law.
 

 
 
 
 
 
 
- 13 -
Exhibit 99.1


INFORMATION


For Immediate Release
November 8, 2012
Contact: 513.271.3700
John A. Kraeutler, Chief Executive Officer


MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER
AND FULL-YEAR 2012 OPERATING RESULTS,
DECLARES REGULAR CASH DIVIDEND, AND REAFFIRMS FISCAL 2013 GUIDANCE

GENERAL HIGHLIGHTS

Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today:

·  
reported record fourth quarter and full-year fiscal 2012 net sales of $43.7 million and $173.5 million, respectively, increases of 6% and 9%, respectively, from the same periods of the prior fiscal year;

·  
reported record fourth quarter and full-year fiscal 2012 operating income of $12.1 million and $49.3 million, respectively, increases of 22% and 23%, respectively, from the same periods of the prior fiscal year;

·  
reported fourth quarter fiscal 2012 net earnings of $8.6 million, or $0.21 per diluted share, increases of 28% and 31%, respectively, compared to the fiscal 2011 fourth quarter.   When compared to the fiscal 2011 fourth quarter net earnings on a non-GAAP basis, the fiscal 2012 fourth quarter net earnings and net earnings per diluted share increased 16% and 17%, respectively.  This non-GAAP basis excludes the effect of costs associated with the consolidation of its Saco, Maine operations into its Tennessee facility (see non-GAAP financial measure reconciliation);

·  
reported record full-year fiscal 2012 net earnings of $33.4 million, or $0.80 per diluted share, increases of 24% and 23%, respectively, compared to fiscal 2011.   On a non-GAAP basis, earnings were $34.0 million, or $0.82 per diluted share, increases of 20% and 19%, respectively.  In fiscal 2012, this non-GAAP basis excludes the effect of costs associated with the consolidation of its Saco, Maine operations into its Tennessee facility; whereas in fiscal 2011, it excludes costs associated with the Maine/Tennessee consolidation, as well as costs associated with reorganizing its sales and marketing leadership  (see non-GAAP financial measure reconciliation);

·  
declared the regular quarterly cash dividend of $0.19 per share for the fourth quarter of fiscal 2012, (indicated annual rate of $0.76 per share), the same as the regular quarterly rate of fiscal 2011;

·  
announced the fiscal 2013 annual indicated cash dividend rate of $0.76 per share, the same as fiscal 2012; and
 
 
·  
reaffirmed its fiscal 2013 guidance of per share diluted earnings between $0.86 and $0.91 on net sales of $190 million to $195 million.

 
 

 

FINANCIAL HIGHLIGHTS (UNAUDITED)
In Thousands, Except per Share Data

 
 
Three Months Ended
September 30,
   
Twelve Months Ended
September 30,
 
 
 
2012
   
2011
   
% Change
   
2012
   
2011
   
% Change
 
Net Sales
  $ 43,694     $ 41,349       6%     $ 173,542     $ 159,723       9%  
Operating Income
    12,052       9,850       22%       49,296       40,033       23%  
Net Earnings
    8,573       6,710       28%       33,371       26,831       24%  
Diluted Earnings per Share
  $ 0.21     $ 0.16       31%     $ 0.80     $ 0.65       23%  
Diluted Earnings per Share excluding effect of plant consolidation costs (2012 and 2011 ) sales and marketing leadership reorganization costs (2011) (see non-GAAP financial measure reconciliation)
  $ 0.21     $ 0.18       17%     $ 0.82     $ 0.69       19%  
 
                                               
 
   
September 30,
 
 
 
2012
   
2011
 
 
 
 
 
 
 
 
 
 
 
 
Cash and Equivalents
  $ 31,593     $ 23,626  
Working Capital
    78,128       75,090  
Shareholders’ Equity
    142,748       138,524  
Total Assets
    161,381       155,493  

CASH DIVIDEND MATTERS

The Board of Directors declared the regular quarterly cash dividend of $0.19 per share for the fourth quarter ended September 30, 2012. The dividend is of record November 19, 2012 and payable November 30, 2012.  The Board of Directors has approved the indicated regular quarterly cash dividend rate of $0.19 per share for fiscal 2013, an annual indicated rate of $0.76 per share, the same as the rate in fiscal 2012.  Guided by the Company’s policy of setting a payout ratio of between 75% and 85% of each fiscal year’s expected net earnings, the actual declaration and amount of dividends will be determined by the Board of Directors in its discretion based upon its evaluation of earnings, cash flow requirements and future business developments, including acquisitions.

FISCAL 2013 GUIDANCE REAFFIRMED

For the fiscal year ending September 30, 2013, management expects net sales to be in the range of $190 million to $195 million and per share diluted earnings to be between $0.86 and $0.91.  The per share estimates assume an increase in average diluted shares outstanding from approximately 41.6 million at fiscal 2012 year end to 41.8 million at fiscal 2013 year end.  The per share estimates include a $0.03 charge to earnings for the Medical Device Tax effective January 1, 2013 and a $0.03 charge to earnings representing the incremental cost of clinical trials for an important new illumi gene ® product over and above the cost of clinical trials for past illumi gene products. The sales and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any additional acquisitions the Company might complete during fiscal 2013.


 
 

 

FINANCIAL CONDITION

The Company’s financial condition is sound.  At September 30, 2012, current assets were $96.6 million compared to current liabilities of $18.5 million, resulting in working capital of $78.1 million and a current ratio of 5.2.  Cash and equivalents were $31.6 million and the Company had 100% borrowing capacity under its $30.0 million commercial bank credit facility.  The Company has no bank-debt obligations outstanding.
 

FOURTH QUARTER AND FISCAL 2012 UNAUDITED OPERATING RESULTS
(In Thousands, Except per Share Data)

The following table sets forth the unaudited comparative results of Meridian on a U.S. GAAP basis for the interim and annual periods of fiscal 2012 and fiscal 2011.

 
   
Three Months Ended
September 30,
   
Twelve Months Ended
September 30,
 
   
2012
   
2011
   
2012
   
2011
 
Net sales
  $ 43,694     $ 41,349     $ 173,542     $ 159,723  
Cost of sales
    15,942       16,352       63,664       59,916  
Cost of sales - Plant consolidation
    -       509       -       509  
     Gross profit
    27,752       24,488       109,878       99,298  
                                 
Operating expenses
                               
     Research and development
    2,834       2,494       10,275       9,822  
     Selling and marketing
    5,730       5,731       22,922       22,772  
     General and administrative
    7,136       5,865       26,372       24,883  
     Plant consolidation costs
    -       548       1,013       548  
     Sales and marketing leadership reorganization
    -       -       -       1,240  
          Total operating expenses
    15,700       14,638       60,582       59,265  
 
                               
Operating income
    12,052       9,850       49,296       40,033  
Other income, net
    89       40       420       467  
     Earnings before income taxes
    12,141       9,890       49,716       40,500  
     Income tax provision
    3,568       3,180       16,345       13,669  
     Net earnings
  $ 8,573     $ 6,710     $ 33,371     $ 26,831  
                                 
Net earnings per basic common share
  $ 0.21     $ 0.16     $ 0.81     $ 0.66  
Basic common shares outstanding
    41,105       40,839       41,080       40,715  
 
                               
Net earnings per diluted common share
  $ 0.21     $ 0.16     $ 0.80     $ 0.65  
Diluted common shares outstanding
    41,629       41,384       41,608       41,358  


 

 

 
 

 


The following table sets forth the unaudited operating segment data for the interim and annual periods in fiscal 2012 and fiscal 2011 (in thousands).

 
 
Three Months Ended
September 30,
   
Twelve Months Ended
September 30,
 
 
 
2012
   
2011
   
2012
   
2011
 
Net sales
 
 
   
 
   
 
   
 
 
U.S. Diagnostics
  $ 27,919     $ 25,126     $ 108,010     $ 97,133  
European Diagnostics
    4,674       5,261       23,000       24,187  
Life Science
    11,101       10,962       42,532       38,403  
 
  $ 43,694     $ 41,349     $ 173,542     $ 159,723  
Operating Income
                               
U.S. Diagnostics
  $ 8,857     $ 8,411     $ 38,234     $ 35,191  
European Diagnostics
    30       418       2,428       2,199  
Life Science
    2,947       1,096       8,473       2,595  
Eliminations
    218       (75 )     161       48  
 
  $ 12,052     $ 9,850     $ 49,296     $ 40,033  

COMPANY COMMENTS

John A. Kraeutler, Chief Executive Officer, said, “Revenues of $43.7 million for the fourth quarter, an increase of 6% which, despite  reflecting negative currency and weaker Life Science ordering patterns, were within the expected guidance range.  U. S. Diagnostics sales were up 11% in the period led by our focus products, which included the illumi gene molecular system, foodborne diagnostics and our tests for H. pylori .  European Diagnostics revenues were flat in local currency, but down 11% when converted to U.S. currency.  Our Life Science sales grew by 1% due to cyclical purchasing weakness coming from our industrial customers.

For the full fiscal year, our global Diagnostics revenues grew by 8%, with U.S. Diagnostics increasing by 11% and European Diagnostics up by 2% on a local currency basis.  In fiscal 2012, 62% of all diagnostic revenues were driven by our focus categories of C. difficile testing (+21%), foodborne disease assays (+13%), and our line of H. pylori stomach ulcer-related tests (+7%).  Meridian Life Science sales increased by 11%, with the Bioline molecular reagent business improving by 15% led by the SensiFAST™ and MyTaq™ product lines and core Life Science revenue increasing by 8%.

Our ability to be financially efficient was demonstrated by gross profit improving to 63% versus 62% for fiscal 2011. Operating income increased to 28% of revenues from 25% in the prior period and after tax margins improved to 19% of revenues, an increase of 2 percentage points.

Looking forward, we believe that we are well-positioned for continued organic growth and operating efficiency.  Approximately 950 clinical labs are current customers using our illumi gene platform, which now includes three simple molecular tests, C. difficile , for hospital associated infections, Group B strep, a serious pathogen that should be monitored during pregnancy, and our recently FDA cleared Group A strep test to diagnose strep throat disease.  While the bulk of these labs are currently using one of our three available assays, more and more are adopting multiple assays. Over 100 are purchasing two assays and several all three assays.  During the period, over 80 assays were placed and 50 new customers acquired. Our illumi gene platform contributed $23+ million in fiscal 2012, and we foresee significant growth in fiscal 2013 based upon these three tests plus 2-3 additional illumi gene tests that are expected to be marketed during the year.  Our illumi gene Mycoplasma pneumoniae test was submitted for FDA clearance this week, and we expect that our test for Bordetella pertussis (whooping cough) will be submitted mid-year.  Our R&D pipeline is excellent and, in addition to the tests above, includes several new rapid immunoassays, as well as two new illumi gene tests for common sexually transmitted diseases.

 
 

 


Growth in our Life Science business is expected to be led by our market expansion efforts that bring the Bioline molecular reagents to the industrial diagnostic segment, in addition to emerging global opportunities for our core bulk life science products.  We believe that fiscal 2013 operating margins will be positively impacted by the consolidation of facilities that was completed in 2012 as we continue to strive for consistent improvement in efficiency.

Fiscal 2012 was a year of important progress in new product development, manufacturing and quality excellence, and market execution.  We expect that fiscal 2013 will be strong.”

William J. Motto, Executive Chairman of the Board, said, “Meridian Bioscience continues to operate efficiently and enjoys strong profit margins and cash flow.  The clear challenge and focus for fiscal 2013 and beyond is to accelerate the growth of net sales.  With new products being introduced along several product lines and our recently re-aligned sales force, we expect strong top-line results.  Our balance sheet is sound and our cash flow comfortably supports working capital requirements, capital expenditures, and cash dividends.  The annual indicated cash dividend rate for fiscal 2013 has been set at $0.76 per share, unchanged from the prior fiscal year.  We are mindful that this rate has been unchanged since fiscal 2010 and intend to consider an increase to the rate when the expected increase in sales and earnings materialize.  From my perspective, Meridian Bioscience has all the necessary ingredients to move into its next stage of growth.  These are exciting times for Meridian and I look forward to reporting the quarterly results for fiscal 2013.”


 
 

 

NON-GAAP FINANCIAL MEASURES
 
In this press release, we have provided information on net earnings and diluted earnings per share excluding the effect of costs associated with the consolidation of our Saco, Maine operations into our Tennessee facility (2012 & 2011) and the reorganizing of our Sales and Marketing Leadership (2011).  We believe this information is useful to an investor in evaluating our performance because:
 
1.  
These measures help investors to more meaningfully evaluate and compare the results of operations from period to period by removing the impact of non-routine costs related to consolidating the Maine operations and reorganizing our Sales and Marketing Leadership; and
 
2.  
These measures are used by our management for various purposes, including evaluating performance against incentive bonus achievement targets, comparing performance from period to period in presentations to our board of directors, and as a basis for strategic planning and forecasting.
 
We have provided reconciliations of net earnings, basic earnings per share and diluted earnings per share, with and without the effects of the plant consolidation and leadership reorganization costs noted above, in the tables below for the fourth quarters and full-year fiscal years ended September 30, 2012 and September 30, 2011.

FOURTH QUARTER AND FISCAL YEAR
GAAP TO NON-GAAP RECONCILATION TABLES
(In Thousands, Except per Share Data)

 
 
Three Months Ended
September 30,
   
Twelve Months Ended
September 30,
 
 
 
2012
   
2011
   
2012
   
2011
 
Net Earnings -
 
 
   
 
   
 
   
 
 
U.S. GAAP basis
  $ 8,573     $ 6,710     $ 33,371     $ 26,831  
Facility Consolidation costs
    -       691       659       691  
Sales & Marketing Leadership Reorganization
    -       -       -       872  
Adjusted Earnings
  $ 8,573     $ 7,401     $ 34,030     $ 28,394  
 
                               
Net Earnings per Basic Common Share -
                               
U.S. GAAP basis
  $ 0.21     $ 0.16     $ 0.81     $ 0.66  
Facility Consolidation costs
    -       0.02       0.02       0.02  
Sales & Marketing Leadership Reorganization
    -       -       -       0.02  
Adjusted Basic EPS
  $ 0.21     $ 0.18     $ 0.83     $ 0.70  
 
                               
Net Earnings per Diluted Common Share -
                               
U.S. GAAP basis
  $ 0.21     $ 0.16     $ 0.80     $ 0.65  
Facility Consolidation costs
    -       0.02       0.02       0.02  
Sales & Marketing Leadership Reorganization
    -       -       -       0.02  
Adjusted Diluted EPS
  $ 0.21     $ 0.18     $ 0.82     $ 0.69  

 
 

 


 
FORWARD LOOKING STATEMENTS
 
 
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements.  Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which may be identified by words such as "estimates", "anticipates", "projects", "plans", "seeks", "may", "will", "expects", "intends", "believes", "should" and similar expressions or the negative versions thereof and which also may be identified by their context.  Such statements, whether expressed or implied, are based upon current expectations of the Company and speak only as of the date made.  The Company assumes no obligation to publicly update or revise any forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.  These statements are subject to various risks, uncertainties and other factors that could cause actual results to differ materially, including, without limitation, the following:
 
 
Meridian's continued growth depends, in part, on its ability to introduce into the marketplace enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by Meridian's competition.  While Meridian has introduced a number of internally developed products, there can be no assurance that it will be successful in the future in introducing such products on a timely basis.  Meridian relies on proprietary, patented and licensed technologies, and the Company’s ability to protect its intellectual property rights, as well as the potential for intellectual property litigation, would impact its results.  Ongoing consolidations of reference laboratories and formation of multi-hospital alliances may cause adverse changes to pricing and distribution.  Recessionary pressures on the economy and the markets in which our customers operate, as well as adverse trends in buying patterns from customers can change expected results.  Costs and difficulties in complying with laws and regulations, including those administered by the United States Food and Drug Administration, can result in unanticipated expenses and delays and interruptions to the sale of new and existing products.  The international scope of Meridian’s operations, including changes in the relative strength or weakness of the U.S. dollar and general economic conditions in foreign countries, can impact results and make them difficult to predict.  One of Meridian's main growth strategies is the acquisition of companies and product lines.  There can be no assurance that additional acquisitions will be consummated or that, if consummated, will be successful and the acquired businesses will be successfully integrated into Meridian's operations.  There may be risks that acquisitions may disrupt operations and may pose potential difficulties in employee retention and there may be additional risks with respect to Meridian’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings or the failure of acquisitions to achieve their plans and objectives.  The Company cannot predict the possible impact of recently-enacted United States healthcare legislation and any similar initiatives in other countries on its results of operations.  In addition to the factors described in this paragraph, Part I, Item 1A Risk Factors of our Form 10-K contains a list and description of uncertainties, risks and other matters that may affect the Company.
 
 
Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com .
 
 
(end)